Replies to post #22 on Genaera Corp fka GENR

[DewDiligence]

>DewDiligence, in your "profile" your investment advice is to avoid genr stock! …would you enlighten us as to why you are so bearish on genr! thank you!<

rick: In a nutshell, I think the company is a quasi-legit scam and will never manage to bring a drug to market.

A systemic anti-angiogenic treatment for AMD is a bad idea (no company other than GENR is pursing such an approach) and it will likely encounter considerable skepticism from the ophthalmic community.

But GENR has an even more pressing problem: they are not enrolling patients in the phase-3 Evizon trial at a fast enough rate to finish in a reasonable amount of time. And things won’t get any easier for GENR once Lucentis is launched.

Since you are a premium iHub member, you can use iHub’s Advanced Search function to pull up my posts on the Biotech Values board about GENR starting in late 2004, which is when I turned bearish. Regards, Dew

p.s. I’ve asked Matt to make Tina the moderator of this board and am awaiting his reply.